Shinya Kimura

Summary

Affiliation: Kyoto University
Country: Japan

Publications

  1. pmc NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor
    Tomoko Niwa
    Discovery Research Laboratories, Nippon Shinyaku Co, Ltd 14, Nishinosho monguchi cho, Kisshoin, Minami Ku, Kyoto 601 8550, Japan
    Anal Chem Insights 2:93-106. 2007
  2. ncbi request reprint Inhibition of leukemic cell growth by a novel anti-cancer drug (GUT-70) from calophyllum brasiliense that acts by induction of apoptosis
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Int J Cancer 113:158-65. 2005
  3. ncbi request reprint NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Blood 106:3948-54. 2005
  4. ncbi request reprint Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Int J Hematol 79:37-43. 2004
  5. ncbi request reprint Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin, Sakyo ku Kyoto 606 8507, Japan
    Recent Pat Anticancer Drug Discov 1:347-55. 2006
  6. ncbi request reprint Nephrotic syndrome with crescent formation and massive IgA deposition following allogeneic bone marrow transplantation for natural killer cell leukemia/lymphoma
    Shinya Kimura
    Department of Transfusion Medicine, Kyoto University Hospital, Kyoto, Japan
    Blood 101:4219-21. 2003
  7. ncbi request reprint INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity
    Asumi Yokota
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto, Japan
    Blood 109:306-14. 2007
  8. ncbi request reprint The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529
    Hidekazu Segawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara Shogoin Sakyo ku, Kyoto 606 8507, Japan
    Leuk Res 29:451-7. 2005
  9. doi request reprint Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer
    Eri Kawata
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606 8507, Japan
    Mol Cancer Ther 7:2904-12. 2008
  10. ncbi request reprint Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth
    Hidekazu Segawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Br J Haematol 130:558-60. 2005

Detail Information

Publications65

  1. pmc NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor
    Tomoko Niwa
    Discovery Research Laboratories, Nippon Shinyaku Co, Ltd 14, Nishinosho monguchi cho, Kisshoin, Minami Ku, Kyoto 601 8550, Japan
    Anal Chem Insights 2:93-106. 2007
    ....
  2. ncbi request reprint Inhibition of leukemic cell growth by a novel anti-cancer drug (GUT-70) from calophyllum brasiliense that acts by induction of apoptosis
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Int J Cancer 113:158-65. 2005
    ..Thus, a novel anti-cancer drug, GUT-70 isolated from the stem bark of C. brasiliense induces caspase-mediated and p53-independent apoptosis to overcome multidrug resistance and may become a potent leukemia therapeutics...
  3. ncbi request reprint NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Blood 106:3948-54. 2005
    ..NS-187 also inhibits Lyn without affecting the phosphorylation of Src, Blk, or Yes. These results suggest that NS-187 may be a potentially valuable novel agent to combat imatinib-resistant Philadelphia-positive (Ph+) leukemia...
  4. ncbi request reprint Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Int J Hematol 79:37-43. 2004
    ..Furthermore, one day of ZOL pretreatment augmented the sensitivity of imatinib and Ara-C. Therefore, concurrent or sequential administration of ZOL with imatinib, HU, Ara-C, or DNR may increase the efficacy of leukemia treatment...
  5. ncbi request reprint Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin, Sakyo ku Kyoto 606 8507, Japan
    Recent Pat Anticancer Drug Discov 1:347-55. 2006
    ..Thus, Bcr-Abl/T315I is an important and challenging target for discovery of CML therapeutics. This review is focused on the three novel compounds reported in the recent patents (2004-2006) which claim the efficacy against Bcr-Abl/T315I...
  6. ncbi request reprint Nephrotic syndrome with crescent formation and massive IgA deposition following allogeneic bone marrow transplantation for natural killer cell leukemia/lymphoma
    Shinya Kimura
    Department of Transfusion Medicine, Kyoto University Hospital, Kyoto, Japan
    Blood 101:4219-21. 2003
    ....
  7. ncbi request reprint INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity
    Asumi Yokota
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto, Japan
    Blood 109:306-14. 2007
    ..Furthermore, cyclosporine A, a P-glycoprotein inhibitor, augmented the in vivo activity of INNO-406 against CNS Ph+ leukemia. These findings indicate that INNO-406 is a promising agent for the treatment of CNS Ph+ leukemia...
  8. ncbi request reprint The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529
    Hidekazu Segawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara Shogoin Sakyo ku, Kyoto 606 8507, Japan
    Leuk Res 29:451-7. 2005
    ..Importantly, YM529 prolonged the survival of NOD/SCID mice engrafted with human primary leukemic cells. These findings indicate that the YM529 may become a novel molecular therapeutic class for treatment of leukemias...
  9. doi request reprint Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer
    Eri Kawata
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606 8507, Japan
    Mol Cancer Ther 7:2904-12. 2008
    ..This study shows the efficacy of i.v. administration of PLK-1 siRNA/atelocollagen for liver metastases of lung cancer. We believe siRNA therapy will be a powerful and promising strategy against advanced lung cancer...
  10. ncbi request reprint Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth
    Hidekazu Segawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Br J Haematol 130:558-60. 2005
    ..These findings suggest that the combination of ZOL and imatinib accelerate the eradication of Ph+ clone, resulting in better prognosis of Ph+ leukaemia patients who have not yet acquired mutations...
  11. ncbi request reprint ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms
    Junya Kuroda
    Division of Haematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kamigyo ku, Kyoto, Japan
    Br J Haematol 140:181-90. 2008
    ..These results suggest that ABT-737 is a useful component of chemotherapies for CML with diverse drug-resistance mechanisms...
  12. doi request reprint Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor
    Rina Nagao
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho, Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Lett 312:91-100. 2011
    ..The combination of AV65 with IM had a synergistic inhibitory effect on the proliferation of CML cells. These findings suggest that AV65 could be a novel therapeutic agent for the treatment of CML...
  13. doi request reprint A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro
    Eri Kawata
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Lett 294:245-53. 2010
    ..Furthermore, ZOL augmented the inhibitory effects of the PLK-1 siRNA. In conclusion, combining a PLK-1 siRNA with ZOL treatment is an attractive strategy against MM...
  14. doi request reprint Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
    Ruriko Tanaka
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Blood 116:2089-95. 2010
    ..These data together support further clinical investigation of AT9283 in patients with imatinib- and second-generation ABL TKI-resistant BCR-ABL(+) cells, including T315I...
  15. doi request reprint beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model
    Eishi Ashihara
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto University Hospital, Kyoto, Japan
    Clin Cancer Res 15:2731-8. 2009
    ..beta-catenin overexpression correlates positively with prognosis in several types of malignancies. We herein assessed its effects on growth of multiple myeloma cells using a xenograft model...
  16. ncbi request reprint Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells
    Masaki Nogawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Japan
    Oncol Res 15:1-9. 2005
    ..Ras does not appear to be the molecular target for ZOL-induced growth inhibition. Prevention of geranylgeranylation rather than farnesylation is an important therapeutic target in prostate cancer...
  17. doi request reprint Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines
    Yasuyuki Deguchi
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin Sakyo ku, Kyoto 606 8507, Japan
    Leuk Res 32:980-3. 2008
    ..Both nilotinib and INNO-406 were potent inhibitors of the dasatinib-resistant T315A, F317L and F317V BCR-ABL mutations...
  18. ncbi request reprint In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations
    Haruna Naito
    Discovery Research Laboratories, Nippon Shinyaku Co, Ltd, 14 Nishinosho Mongucgi Cho, Minami Ku, Kyoto 601 8550, Japan
    Leuk Res 30:1443-6. 2006
    ..Furthermore, NS-187 prolonged the survival of mice injected with leukemic cells expressing all mutated Bcr-Abl tested except T315I, and its efficacy correlated well with its in vitro effects...
  19. ncbi request reprint A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo
    Takeshi Yuasa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Clin Cancer Res 11:853-9. 2005
    ..Minodronic acid (YM529) is a third-generation nitrogen-containing bisphosphonate. Here, we have investigated the therapeutic efficacy of YM529 against renal cell cancer (RCC) alone or in combination with IFN both in vitro and in vivo...
  20. ncbi request reprint Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy
    Kiyoshi Sato
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Int J Cancer 116:94-9. 2005
    ..These findings show that ZOL significantly stimulated the proliferation of gammadeltaT cells and that gammadeltaT cells required pre-treatment with ZOL for cytotoxic activity against target cells...
  21. ncbi request reprint p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid
    Junya Kuroda
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Sci 95:186-92. 2004
    ..ZOL also affected the coordinate expression patterns of several cell cycle regulators during the execution of anti-tumor activity...
  22. doi request reprint Monitoring with a non-invasive bioluminescent in vivo imaging system of pleural metastasis of lung carcinoma
    Seiji Matsumoto
    Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Kyoto, Japan
    Lung Cancer 66:75-9. 2009
    ..We established a MPE model and investigated the therapeutic effects of the administration of serial doses of docetaxel on intrathoracic disseminated foci using an in vivo image system (IVIS)...
  23. ncbi request reprint Intraoperative blood loss during living donor liver transplantation: an analysis of 635 recipients at a single center
    Takeshi Yuasa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Transfusion 45:879-84. 2005
    ....
  24. ncbi request reprint Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models
    Masaki Nogawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606 8507, Japan
    Cancer Lett 217:243-53. 2005
    ..We believe the models we have established in combination with the in vivo imaging system will be highly useful for future studies of metastasis and the testing of anti-metastatic therapies...
  25. ncbi request reprint The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis
    Naoyuki Horie
    Department of Orthopaedics, Graduate School of Medical Science Kyoto Prefectural University of Medicine, 465 Kawaramachi Hirokoji, Kyoto, 602 8566, Japan
    Cancer Lett 238:111-8. 2006
    ..These observations suggest that third-generation BPs directly affect on the proliferation and survival of osteosarcoma cells, which supports the possibility that they could be beneficial in the treatment of osteosarcoma patients...
  26. pmc Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer
    Masaki Nogawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    J Clin Invest 115:978-85. 2005
    ..We believe intravesical siRNA instillation against bladder cancer will be useful as a therapeutic tool...
  27. doi request reprint Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells
    Miki Takeuchi
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Cancer Sci 102:591-6. 2011
    ..In conclusion, Rakicidin A is a promising compound for targeting TKI-resistant quiescent CML stem cells in the hypoxic BM environment...
  28. doi request reprint Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia
    Junya Kuroda
    Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kamigyo ku, Kyoto, Japan
    Mol Cancer Res 8:994-1001. 2010
    ....
  29. ncbi request reprint Antidonor antibody in patients receiving ABO-identical and HLA-mismatched living donor liver transplants: effect on survival
    Eishi Ashihara
    Department of Blood Transfusion and Cell Therapy, Kyoto, Japan
    Transplantation 83:506-9. 2007
    ..5%; negative group, 81.9%; P=3.3x10). We conclude that antidonor antibodies have adverse effects on the clinical outcome of LDLTs, and that being female and/or older aged (>or=18 years of age) are risk factors for LDLT...
  30. doi request reprint Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation
    Ruriko Tanaka
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara Sakyo ku Kyoto 606 8507, Japan
    Expert Rev Anticancer Ther 8:1387-98. 2008
    ....
  31. doi request reprint Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis
    Kazuki Sakai
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Eur J Immunol 41:67-75. 2011
    ..In conclusion, Gal-9 ameliorates aGVHD, possibly by inducing T-cell apoptosis, suggesting that gal-9 may be an attractive candidate for the treatment of aGVHD...
  32. doi request reprint Osteoclasts are involved in the maintenance of dormant leukemic cells
    Asumi Yokota
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Leuk Res 34:793-9. 2010
    ..The results of our in vitro experiments suggest that OCs could be involved in the maintenance of dormant leukemic cells in the bone marrow (BM) microenvironment through the release of soluble factors, one of which could be TGF-beta...
  33. doi request reprint Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients
    Ruriko Tanaka
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Japan
    Cancer Lett 312:228-34. 2011
    ..Thus, the QP and MBP-QP may become useful methods for the management of ABL TKI-treated patients...
  34. ncbi request reprint Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines
    Seiji Matsumoto
    Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Kyoto 606 8507, Japan
    Lung Cancer 47:31-9. 2005
    ..These findings indicate that ZOL and combined use of these agents may be promising therapeutic strategies for SCLC...
  35. ncbi request reprint The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate
    Junya Kuroda
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Blood 102:2229-35. 2003
    ..These findings indicate that ZOL is a potent antileukemic agent that augments synergistically the anti-Ph+ leukemia activity of imatinib mesylate...
  36. doi request reprint JAK2V617F-positive essential thrombocythemia and multiple myeloma with IGH/CCND1 gene translocation coexist, but originate from separate clones
    Junya Kuroda
    Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Acta Haematol 120:177-81. 2008
    ....
  37. ncbi request reprint The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
    Taira Maekawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho, Shogoin, Sakyo ku 606 8507, Japan
    Int J Clin Oncol 12:327-40. 2007
    ....
  38. doi request reprint Fully automated and super-rapid system for the detection of JAK2V617F mutation
    Ruriko Tanaka
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto 606 8507, Japan
    Leuk Res 32:1462-7. 2008
    ..The presence of JAK2V617F mutation in these 7 specimens was confirmed by allele-specific PCR. These findings indicate that QP-system is more sensitive and useful than direct sequencing for diagnoses of CMPDs...
  39. ncbi request reprint Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface
    Ryo Uchida
    Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Biochem Biophys Res Commun 354:613-8. 2007
    ..In conclusion, gammadeltaT cells recognize the mevalonate metabolites and ICAM-1 on myeloma cells...
  40. pmc Noninvasive tracking of donor cell homing by near-infrared fluorescence imaging shortly after bone marrow transplantation
    Takashi Ushiki
    Department of Radiation Oncology and Image Applied Therapy, Kyoto University Graduate School of Medicine, Kyoto, Japan
    PLoS ONE 5:e11114. 2010
    ..Noninvasive observation of donor cell homing shortly after transplantation is potentially valuable for improving therapeutic outcomes of BMT by diagnosing the early stages of these diseases...
  41. ncbi request reprint Rapid quantitation of immunoglobulin G antibodies specific for blood group antigens A and B by surface plasmon resonance
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kawahara cho Shogoin, Sakyo ku, Kyoto, Japan
    Transfusion 45:56-62. 2005
    ..Currently existing methods to detect IgG anti-A/B suffer limitations owing to high costs, low throughput, and poor adaptability to automation...
  42. doi request reprint Circulating endothelial progenitor cells decreased in patients with sclerodermatous chronic graft-versus-host disease
    Kazuho Shimura
    Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Biol Blood Marrow Transplant 14:426-37. 2008
    ..In conclusion, s-cGVHD patients show findings consistent with those seen in PSS with impaired vasculogenesis that may limit blood perfusion and may contribute to the development of sclerodermatous lesions...
  43. ncbi request reprint [Detection of antibodies specific for blood group antigens A and B]
    Kimiko Yurugi
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606 8507
    Rinsho Byori 53:1011-8. 2005
    ..Therefore, we have developed a method based on surface plasmon resonance (SPR) that detects the presence of the antigen-antibody complex without any labeling. This method allows us to rapidly quantitate anti-A/B IgG Ab levels...
  44. ncbi request reprint New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Curr Pharm Biotechnol 7:371-9. 2006
    ..It may be necessary for the improvement of CML and Ph(+)ALL treatment to be taken into consideration of the combination therapy with novel ATP-competitive inhibitors and these agents...
  45. ncbi request reprint Comparison of human herpes virus 8 related primary effusion lymphoma with human herpes virus 8 unrelated primary effusion lymphoma-like lymphoma on the basis of HIV: report of 2 cases and review of 212 cases in the literature
    Yutaka Kobayashi
    Division of Hematology and Oncology, Department of Internal Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Acta Haematol 117:132-44. 2007
    ..This primary lymphomatous effusion includes human herpes virus 8 (HHV8)-related primary effusion lymphoma (PEL) and HHV8-unrelated PEL-like lymphoma. We attempted to clarify the nature of the primary lymphomatous effusion...
  46. ncbi request reprint Human leukocyte antigens in Japanese patients with biliary atresia: retrospective analysis of patients who underwent living donor liver transplantation
    Takeshi Yuasa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Hum Immunol 66:295-300. 2005
    ..We speculate that a gene at the locus close to HLA plays an important role in the pathogenesis of BA...
  47. doi request reprint Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of γδT cells
    Eishi Ashihara
    Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Kyoto, Japan Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan Electronic address
    Biochem Biophys Res Commun 463:650-5. 2015
    ..These observations indicate that IPP activates the chemotaxis of γδT cells toward target MM cells treated with ZOL. ..
  48. doi request reprint [Cancer immunotherapy using gammadelta T cells ex vivo expanded by bisphosphonate]
    Shinya Kimura
    Kyoto University Hospital, Department of Transfusion Medicine and Cell Therapy
    Clin Calcium 18:499-505. 2008
    ..Based on these pre-clinical studies, several clinical trials which focus on the antitumor effects of BPs have already started...
  49. ncbi request reprint [Novel molecular target therapy]
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital
    Nihon Rinsho 65:46-51. 2007
  50. doi request reprint Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia
    Seiichiro Katagiri
    First Department of Internal Medicine, Tokyo Medical University, Shinjuku ku, Tokyo, Japan
    Clin Cancer Res 19:1422-32. 2013
    ..The clear link between the Hedgehog pathway and BCR-ABL1-positive leukemia led to an effort to identify small molecules to block the pathway...
  51. ncbi request reprint Zoledronic acid - a multiplicity of anti-cancer action
    Takeshi Yuasa
    Department of Urology, Akita University School of Medicine, 1 1 1 Hondo, Akita, Japan
    Curr Med Chem 14:2126-35. 2007
    ..The accumulated encouraging evidence to date indicate that ZOL is an attractive anti-cancer agent which promises to be the next exciting therapy for patients with various cancers...
  52. ncbi request reprint [Novel anti-CML agents beyond imatinib]
    Shinya Kimura
    Rinsho Ketsueki 48:475-84. 2007
  53. ncbi request reprint [Targeting Ras related proteins for leukemia therapy]
    Shinya Kimura
    Rinsho Ketsueki 46:179-86. 2005
  54. pmc Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
    Junya Kuroda
    The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia
    Proc Natl Acad Sci U S A 103:14907-12. 2006
    ..These results demonstrate that Bim and Bad account for most, perhaps all, imatinib-induced killing of Bcr/Abl+ leukemic cells and suggest previously undescribed drug combination strategies for cancer therapy...
  55. doi request reprint Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification
    Koji Morinaga
    Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
    Int J Cancer 122:2621-7. 2008
    ..Because BCR-ABL gene amplification occurs in blast crisis, these inhibitors might overcome IM resistance in such patients' leukemia...
  56. doi request reprint Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin
    Junya Kuroda
    Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii cho, Kamigyo ku, Kyoto 602 8566, Japan
    Int J Hematol 87:507-15. 2008
    ..These results suggest that HHT could constitute an attractive option for MM treatment though its ability to simultaneously target multiple tumor-promoting molecules...
  57. ncbi request reprint [Molecular targeting therapy for chronic myeloid leukemia]
    Shinya Kimura
    Rinsho Ketsueki 48:46-55. 2007
  58. doi request reprint CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
    Linhua Jin
    Department of Clinical Pathology, Juntendo University School of Medicine, Tokyo, Japan
    Mol Cancer Ther 7:48-58. 2008
    ..Altogether, these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells...
  59. ncbi request reprint [Cell therapy. 1. Donor lymphocyte infusion therapy]
    Junya Kuroda
    Nihon Naika Gakkai Zasshi 93:1392-7. 2004
  60. ncbi request reprint Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis
    Toshitatsu Takao
    Am J Hematol 77:419-20. 2004
  61. ncbi request reprint Comprehensive cytogenetic study by spectral karyotyping on blastic natural killer cell leukemia/lymphoma
    Naoto Jyoko
    Am J Hematol 69:234-5. 2002
  62. ncbi request reprint Real-time monitoring of antibody secretion from B-cells on a microchip stimulated with a minute amount of mitogen
    Tatsuya Munaka
    Technology Research Laboratory, Shimadzu Corporation, 3 9 4 Hikari dai, Seika cho, Soraku gun, Kyoto 619 0237, Japan
    Analyst 132:512-4. 2007
    ....
  63. ncbi request reprint siRNA targeting PLK-1 induces apoptosis of synoviocytes in rheumatoid arthritis
    Makoto Wada
    Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii cho, Kawaramachi Hirokoji, Kamigyo ku, Kyoto 602 8566, Japan
    Biochem Biophys Res Commun 357:353-9. 2007
    ..These findings suggest that PLK-1 plays a critical role in the proliferation of RA synoviocytes leading to bone destruction, and siRNA against PLK-1 is potentially useful for the treatment of RA...
  64. ncbi request reprint [Combination therapy with rituximab and cladribine for patients with follicular lymphoma]
    Yutaka Kobayashi
    Dept of Hematology and Immunology, Kyoto Second Red Cross Hospital
    Gan To Kagaku Ryoho 34:1623-7. 2007
    ..There was no apparent thrombocytopenia or anemia. Herpes zoster was observed after treatment in 1 patient. RC is considered highly effective and well tolerated...